Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25240833 | 0.96 | LRRK2 (0.33) | LRRK2DHFRALOX5APFEN1PDE10A | |
| Formic Acid SCHEMBL30467746 | 0.96 | LRRK2 (0.33) | LRRK2DHFRALOX5APFEN1PDE10A | |
| SCHEMBL26771379 | 0.92 | LRRK2 (0.36) | LRRK2DHFRALOX5APFEN1PDE10A | |
| SCHEMBL25240830 | 0.87 | LRRK2 (0.32) | LRRK2DHFRALOX5APFEN1PDE10A | |
| SCHEMBL24252260 | 0.80 | PDE10A (0.46) | LRRK2DHFRPDE10A | |
| SCHEMBL30467809 | 0.80 | PDE10A (0.46) | LRRK2DHFRPDE10A | |
| SCHEMBL26779469 | 0.79 | LRRK2 (0.32) | LRRK2ALOX5APFEN1 | |
| SCHEMBL24252763 | 0.78 | PDE10A (0.35) | LRRK2DHFRPDE10A | |
| SCHEMBL30467655 | 0.77 | PDE10A (0.38) | LRRK2DHFRPDE10A | |
| SCHEMBL24252278 | 0.77 | PDE10A (0.40) | LRRK2DHFRALOX5APFEN1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | LRRK2 1477/4885DHFR 1380/4885ALOX5AP 246/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | LRRK2 1477/4885DHFR 1380/4885ALOX5AP 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.